Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Non-Inferiority 'Mistake' Hits E-Therapeutics' Depression Ambition

This article was originally published in Scrip

Executive Summary

"Our mistake was to structure the trial as a non-inferiority to amitriptyline study," e-Therapeutics CEO Malcolm Young told Scrip. "We should have called it a 'dose-ranging' study – which is what it was." The company saw its share price plummet on Feb. 15 following top-line results from its Phase IIb trial of ETS6103 (a controlled-release formulation of the analgesic tramadol) in major depressive disorder, which failed to meet its efficacy endpoint of establishing non-inferiority when compared to amitriptyline.

You may also be interested in...

Can Barlow Flip E-Therapeutics From A Miss To A Hit?

Dr Raymond Barlow, the newly appointed CEO of e-Therapeutics, is hoping he can turn the lackluster business around and reposition it as a show stealing co-star for efficient drug discovery partnering, utilizing its bioinformatics platform technology.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts